electroCore to Attend HC Wainwright’s 26th Annual Global Investment Conference

ROCKAWAY, NJ, Sept. 04, 2024 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will be participating in the 26th Annual Electron Microelectronics Conference^He HC Wainwright Annual Global Investment Conference to be held in New York City from September 9-11, 2024.

Dan Goldberger, CEO of the company, will participate in a fireside chat on Wednesday, September 11.^Heat 12:00 p.m. ET. Mr. Goldberger will also be available for one-on-one meetings on the same day.

For more information about the conference and to register, please visit the conference page here.

About electroCore, Inc.
electroCore, Inc. is a commercial-stage bioelectronic medicine and wellness company dedicated to improving health through its noninvasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote overall wellness and human performance in the United States and select foreign markets.

For more information, visit www.electrocore.com.

Forward-looking statements
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements regarding electroCore’s business prospects and clinical and product development plans (including with respect to ongoing studies); its potential portfolio or markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the issuance of U.S. and international patents providing expanded intellectual property coverage; the possibility of future business models and revenue streams from the Company’s potential use of nVNS for rare CT scans in general and SUNCT/SUNA in particular, the potential of nVNS in general and gammaCore in particular and other statements that are not historical in nature, particularly those that use terminology such as “anticipates,” “will,” “expects,” “believes,” “intends,” other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statement due to numerous factors. Such factors include, but are not limited to, the ability to raise additional financing necessary to continue electroCore’s business and product development plans, the inherent uncertainties associated with the development of new products or technologies, the ability to commercialize gammaCore, the potential impact and effects of COVID-19 on electroCore’s business, electroCore’s operating results and financial performance, and any measures electroCore has taken and may take in response to COVID-19 and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and general market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore undertakes no obligation to update any forward-looking statements or to update the reasons why actual results could differ from those projected in any forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also consult the risk factor disclosures set forth in electroCore’s reports and other documents filed with the SEC available at www.sec.gov.

The story continues

Contact:
ECOR Investor Relations
(973) 302-9253
[email protected]